Vanda Pharmaceuticals (VNDA) to Release Earnings on Wednesday

Vanda Pharmaceuticals (NASDAQ:VNDA) is expected to release its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect Vanda Pharmaceuticals to post earnings of ($0.6880) per share and revenue of $54.9780 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) EPS for the quarter, missing analysts’ consensus estimates of ($2.18) by ($0.21). The firm had revenue of $57.22 million for the quarter, compared to analysts’ expectations of $59.28 million. Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%. On average, analysts expect Vanda Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Vanda Pharmaceuticals Price Performance

VNDA opened at $7.00 on Monday. The business’s fifty day moving average is $7.58 and its two-hundred day moving average is $6.76. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.38 and a current ratio of 2.39. The company has a market cap of $420.95 million, a price-to-earnings ratio of -1.88 and a beta of 0.65. Vanda Pharmaceuticals has a one year low of $3.81 and a one year high of $9.94.

Analyst Upgrades and Downgrades

A number of research firms have commented on VNDA. HC Wainwright boosted their target price on Vanda Pharmaceuticals from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, February 23rd. Zacks Research lowered Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 18th. UBS Group reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, January 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Monday, April 20th. Finally, Truist Financial started coverage on shares of Vanda Pharmaceuticals in a research note on Thursday, March 5th. They issued a “buy” rating and a $18.00 target price for the company. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $14.90.

Insider Activity

In related news, CEO Mihael Hristos Polymeropoulos sold 156,235 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $8.17, for a total transaction of $1,276,439.95. Following the transaction, the chief executive officer directly owned 2,704,496 shares in the company, valued at approximately $22,095,732.32. This represents a 5.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Timothy Williams sold 42,434 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $8.27, for a total value of $350,929.18. Following the transaction, the senior vice president owned 377,450 shares in the company, valued at $3,121,511.50. This trade represents a 10.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 314,342 shares of company stock valued at $2,583,985 in the last three months. Company insiders own 10.00% of the company’s stock.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. increased its stake in Vanda Pharmaceuticals by 456.6% during the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 5,328 shares during the last quarter. Quarry LP acquired a new stake in Vanda Pharmaceuticals during the third quarter worth about $53,000. Cerity Partners LLC acquired a new stake in Vanda Pharmaceuticals during the second quarter worth about $69,000. Boothbay Fund Management LLC acquired a new stake in Vanda Pharmaceuticals during the third quarter worth about $72,000. Finally, Engineers Gate Manager LP acquired a new stake in Vanda Pharmaceuticals during the second quarter worth about $75,000. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.